Clinical proteomics: Translating benchside promise into bedside reality

Emanuel F. Petricoin; Kathryn C. Zoon; Elise C. Kohn; J. Carl Barrett; Lance A. Liotta

doi:10.1038/nrd891

Clinical proteomics: Translating benchside promise into bedside reality

Emanuel F. Petricoin^*
, Kathryn C. Zoon
, Elise C. Kohn
, J. Carl Barrett
, Lance A. Liotta

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

510 Scopus citations

Abstract

The ultimate goal of proteomics is to characterize the information flow through protein networks. This information can be a cause, or a consequence, of disease processes. Clinical proteomics is an exciting new subdiscipline of proteomics that involves the application of proteomic technologies at the bedside, and cancer, in particular, is a model disease for studying such applications. Here, we describe proteomic technologies that are being developed to detect cancer earlier, to discover the next generation of targets and imaging biomarkers, and finally to tailor the therapy to the patient.

Original language	English
Pages (from-to)	683-695
Number of pages	13
Journal	Nature Reviews Drug Discovery
Volume	1
Issue number	9
DOIs	https://doi.org/10.1038/nrd891
State	Published - Sep 2002
Externally published	Yes

Access to Document

10.1038/nrd891

Cite this

@article{96edcba95fb34795ac117014a99998a0,

title = "Clinical proteomics: Translating benchside promise into bedside reality",

abstract = "The ultimate goal of proteomics is to characterize the information flow through protein networks. This information can be a cause, or a consequence, of disease processes. Clinical proteomics is an exciting new subdiscipline of proteomics that involves the application of proteomic technologies at the bedside, and cancer, in particular, is a model disease for studying such applications. Here, we describe proteomic technologies that are being developed to detect cancer earlier, to discover the next generation of targets and imaging biomarkers, and finally to tailor the therapy to the patient.",

author = "Petricoin, \{Emanuel F.\} and Zoon, \{Kathryn C.\} and Kohn, \{Elise C.\} and Barrett, \{J. Carl\} and Liotta, \{Lance A.\}",

year = "2002",

month = sep,

doi = "10.1038/nrd891",

language = "English",

volume = "1",

pages = "683--695",

journal = "Nature Reviews Drug Discovery",

issn = "1474-1776",

publisher = "Nature Research",

number = "9",

}

TY - JOUR

T1 - Clinical proteomics

T2 - Translating benchside promise into bedside reality

AU - Petricoin, Emanuel F.

AU - Zoon, Kathryn C.

AU - Kohn, Elise C.

AU - Barrett, J. Carl

AU - Liotta, Lance A.

PY - 2002/9

Y1 - 2002/9

N2 - The ultimate goal of proteomics is to characterize the information flow through protein networks. This information can be a cause, or a consequence, of disease processes. Clinical proteomics is an exciting new subdiscipline of proteomics that involves the application of proteomic technologies at the bedside, and cancer, in particular, is a model disease for studying such applications. Here, we describe proteomic technologies that are being developed to detect cancer earlier, to discover the next generation of targets and imaging biomarkers, and finally to tailor the therapy to the patient.

AB - The ultimate goal of proteomics is to characterize the information flow through protein networks. This information can be a cause, or a consequence, of disease processes. Clinical proteomics is an exciting new subdiscipline of proteomics that involves the application of proteomic technologies at the bedside, and cancer, in particular, is a model disease for studying such applications. Here, we describe proteomic technologies that are being developed to detect cancer earlier, to discover the next generation of targets and imaging biomarkers, and finally to tailor the therapy to the patient.

UR - https://www.scopus.com/pages/publications/0036718796

U2 - 10.1038/nrd891

DO - 10.1038/nrd891

M3 - Review article

C2 - 12209149

AN - SCOPUS:0036718796

SN - 1474-1776

VL - 1

SP - 683

EP - 695

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

IS - 9

ER -

Clinical proteomics: Translating benchside promise into bedside reality

Abstract

Access to Document

Fingerprint

Cite this